HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
50 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
DPP4
dipeptidyl peptidase 4
Chromosome 2 · 2q24.2
NCBI Gene: 1803Ensembl: ENSG00000197635.11HGNC: HGNC:3009UniProt: A0A7I2V2X8
619PubMed Papers
20Diseases
22Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Hub GeneProteaseReceptor
RESEARCH IMPACT
Highly StudiedTrending
CLINICAL
FDA Approved Target
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
lysosomal membranefocal adhesioncell surfacemembranetype 2 diabetes mellitusdiabetes mellitusintelligencesmoking initiation
✦AI Summary

DPP4 is a serine protease with multifaceted roles extending beyond its catalytic activity. Enzymatically, DPP4 cleaves dipeptides from substrates and functions as a signaling receptor, including serving as a receptor for MERS-CoV-2 1. In skin biology, DPP4 marks a major fibroblast population (SFRP2+) involved in matrix deposition and inflammatory processes 1. DPP4's pathological significance spans multiple diseases. In rheumatoid arthritis, DPP4 undergoes ubiquitin-dependent degradation by the E3 ligase Mid1; DPP4 loss paradoxically promotes synovial cell proliferation and inflammation, suggesting DPP4 normally restrains synovial activation 2. In hypertrophic scarring, DPP4 promotes TGFβ1-mediated myofibroblast differentiation and extracellular matrix overproduction; DPP4 inhibition reduces fibrosis 3. In osteoarthritis, DPP4 exacerbates progression through enzyme-independent mechanisms by promoting mitochondrial dysfunction and chondrocyte senescence via interaction with MYH9 4. In hepatocellular carcinoma, DPP4 upregulation by ketogenic metabolites enhances ferroptosis susceptibility 5. In aortic valve calcification, DPP4 stabilization through reduced ubiquitination promotes osteogenic differentiation 6. In lung cancer, DPP4 drives metabolic reprogramming of drug-tolerant persisters through fatty acid oxidation and antioxidant pathways 7. DPP4 genetic variants associate with drug-induced bullous pemphigoid risk in diabetic patients 8. These findings position DPP4 as a multifunctional therapeutic target across inflammatory, fibrotic, and malignant diseases.

Sources cited
1
DPP4 marks a major fibroblast population involved in matrix deposition and inflammatory cell retention
PMID: 29080679
2
Mid1 promotes synovial activation by ubiquitin-mediated proteasomal degradation of DPP4; DPP4 loss increases synovial cell proliferation and inflammation
PMID: 38777113
3
DPP4 is upregulated in hypertrophic scars and promotes myofibroblast differentiation and extracellular matrix production; DPP4 inhibition improves scar quality
PMID: 34716325
4
DPP4 exacerbates osteoarthritis through enzyme-independent promotion of chondrocyte senescence and mitochondrial dysfunction via MYH9 interaction
PMID: 39680708
5
HMGCL-induced β-hydroxybutyrate upregulates DPP4 to enhance ferroptosis susceptibility in hepatocellular carcinoma
PMID: 36508088
6
DUSP26 promotes aortic valve calcification by antagonizing MDM2-mediated ubiquitination and degradation of DPP4
PMID: 34179958
7
DPP4 drives metabolic reprogramming of lung cancer persisters through fatty acid oxidation and Nrf2-mediated antioxidant pathway
PMID: 40479551
8
DPP4 gene variants rs3788979 and rs12617656 associate with increased risk of DPP4 inhibitor-induced bullous pemphigoid
PMID: 41373842
Disease Associationsⓘ20
type 2 diabetes mellitusOpen Targets
0.64Moderate
diabetes mellitusOpen Targets
0.63Moderate
intelligenceOpen Targets
0.47Moderate
smoking initiationOpen Targets
0.45Moderate
neurodegenerative diseaseOpen Targets
0.44Moderate
hyperlipidemiaOpen Targets
0.42Moderate
asthmaOpen Targets
0.41Moderate
mathematical abilityOpen Targets
0.40Weak
strokeOpen Targets
0.38Weak
myocardial infarctionOpen Targets
0.38Weak
kidney failureOpen Targets
0.38Weak
prediabetes syndromeOpen Targets
0.37Weak
type 1 diabetes mellitusOpen Targets
0.36Weak
chronic kidney diseaseOpen Targets
0.35Weak
Microscopic hematuriaOpen Targets
0.34Weak
metabolic diseaseOpen Targets
0.33Weak
rheumatoid arthritisOpen Targets
0.33Weak
Alzheimer diseaseOpen Targets
0.31Weak
autism spectrum disorderOpen Targets
0.31Weak
attention deficit hyperactivity disorderOpen Targets
0.31Weak
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Drug Targets22
ALOGLIPTINApproved
Dipeptidyl peptidase IV inhibitor
diabetes mellitus
ALOGLIPTIN BENZOATEApproved
Dipeptidyl peptidase IV inhibitor
type 2 diabetes mellitus
ANAGLIPTINApproved
Dipeptidyl peptidase IV inhibitor
type 2 diabetes mellitus
BEGELOMABPhase III
Dipeptidyl peptidase IV inhibitor
BISEGLIPTINPhase II
Dipeptidyl peptidase IV inhibitor
type 2 diabetes mellitus
CARMEGLIPTINPhase II
Dipeptidyl peptidase IV inhibitor
type 2 diabetes mellitus
DBPR-108Phase III
Dipeptidyl peptidase IV inhibitor
type 2 diabetes mellitus
DUTOGLIPTINPhase III
Dipeptidyl peptidase IV inhibitor
type 2 diabetes mellitus
EVOGLIPTINApproved
Dipeptidyl peptidase IV inhibitor
diabetes mellitus
GEMIGLIPTINApproved
Dipeptidyl peptidase IV inhibitor
diabetes mellitus
GOSOGLIPTINPhase III
Dipeptidyl peptidase IV inhibitor
type 2 diabetes mellitus
LINAGLIPTINApproved
Dipeptidyl peptidase IV inhibitor
type 2 diabetes mellitus
OMARIGLIPTINApproved
Dipeptidyl peptidase IV inhibitor
type 2 diabetes mellitus
SAXAGLIPTIN HYDROCHLORIDEApproved
Dipeptidyl peptidase IV inhibitor
type 2 diabetes mellitus
SITAGLIPTINApproved
Dipeptidyl peptidase IV inhibitor
diabetes mellitus
SITAGLIPTIN FUMARATEApproved
Dipeptidyl peptidase IV inhibitor
type 2 diabetes mellitus
SITAGLIPTIN HYDROCHLORIDE MONOHYDRATEApproved
Dipeptidyl peptidase IV inhibitor
type 2 diabetes mellitus
SITAGLIPTIN PHOSPHATEApproved
Dipeptidyl peptidase IV inhibitor
type 2 diabetes mellitus
TENELIGLIPTINApproved
Dipeptidyl peptidase IV inhibitor
diabetes mellitus
TRELAGLIPTINPhase III
Dipeptidyl peptidase IV inhibitor
metabolic disease
TRELAGLIPTIN SUCCINATEApproved
Dipeptidyl peptidase IV inhibitor
type 2 diabetes mellitus
VILDAGLIPTINApproved
Dipeptidyl peptidase IV inhibitor
type 2 diabetes mellitus
Related Genes
CXCR4Protein interaction100%ADAProtein interaction100%GCGProtein interaction100%ERVW-1Protein interaction100%ENPEPProtein interaction99%PTPRCProtein interaction98%
Tissue Expression6 tissues
Liver
100%
Lung
77%
Heart
28%
Ovary
21%
Bone Marrow
9%
Brain
8%
Gene Interaction Network
Click a node to explore
DPP4CXCR4ADAGCGERVW-1ENPEPPTPRC
PROTEIN STRUCTURE
Preparing viewer…
PDB4A5S · 1.62 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.90LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.74 [0.61–0.90]
RankingsWhere DPP4 stands among ~20K protein-coding genes
  • #374of 20,598
    Most Researched619 · top 5%
  • #102of 1,025
    FDA-Approved Drug Targets15 · top 10%
  • #8,137of 17,882
    Most Constrained (LOEUF)0.90
Genes detectedDPP4
Sources retrieved50 papers
Response time—
📄 Sources
50▼
1
SFRP2/DPP4 and FMO1/LSP1 Define Major Fibroblast Populations in Human Skin.
PMID: 29080679
J Invest Dermatol · 2018
1.00
2
Mid1 promotes synovitis in rheumatoid arthritis via ubiquitin-dependent post-translational modification.
PMID: 38777113
Pharmacol Res · 2024
0.90
3
Functional characterization of DPP4 and FcRn as receptor and coreceptor for classical human astroviruses in Caco-2 cells.
PMID: 40680075
PLoS Pathog · 2025
0.84
4
The neonatal Fc receptor is a cellular receptor for human astrovirus.
PMID: 39578577
Nat Microbiol · 2024
0.82
5
Structural basis for human DPP4 receptor recognition by a pangolin MERS-like coronavirus.
PMID: 39514585
PLoS Pathog · 2024
0.80